Biosimilar spat erupts again in Europe
This article was originally published in Scrip
The European biotechnology industry body EuropaBio says that the labeling of biosimilar medicines should make clear whether the data used for their approval were generated for the biosimilar or its reference product, and should include information on the reasons for any extrapolation of indications.
You may also be interested in...
Russia seeks WHO endorsement of its Sputnik V vaccine, a UK BioIndustry Association taskforce identifies potential new antibody cocktails, and the European Centre for Disease Prevention and Control considers the best strategies for targeted vaccination programs.
New guidance from the UK covers the recognition of EU approvals, accelerated assessment, rolling reviews, and much else besides.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.